Hema Parmar

1.9k citations

23 papers · 1.4k indexed · h-index 13

Impact in

Oncology top 5%
- Cancer Cells and Metastasis
- HER2/EGFR in Cancer Research
- Cytokine Signaling Pathways and Interactions
Genetics top 5%
- Estrogen and related hormone effects

Papers in

Oncology 14
- Cancer Treatment and Pharmacology 5
- HER2/EGFR in Cancer Research 3
- Cancer Cells and Metastasis 3
Genetics 3
- Chronic Lymphocytic Leukemia Research 3
- Estrogen and related hormone effects 3

Co-authors: Gerald R. Cunha Dale C. Leitman Gary L. Firestone Sreenivasan Paruthiyil Andrew Matus Robert J. Motzer R Nadeau Ashok Rakhit
Journals: Cancer Research (6 papers)Journal of Clinical Oncology (3 papers)Annals of Oncology (2 papers)Cancer (1 paper)Gene (1 paper)
Partner nations: United States Spain Switzerland

In The Last Decade

Hema Parmar

22 papers receiving 1.4k citations

Peers

Countries citing papers authored by Hema Parmar

Since Specialization

Citations

This map shows the geographic impact of Hema Parmar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hema Parmar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hema Parmar more than expected).

Fields of papers citing papers by Hema Parmar

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Hema Parmar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hema Parmar. The network helps show where Hema Parmar may publish in the future.

Co-authors

The 25 scholars most cited alongside Hema Parmar, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Hema Parmar Line = papers co-authored together Hema Parmar links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Multicenter, Open-Label, Phase 3 Study of Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Recipients with Epstein-Barr Virus-Driven Post Transplant Lymphoproliferative Disease after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE) Blood ·Susan E. Prockop, Kris M. Mahadeo, Amer Beitinjaneh, Sylvain Choquet, Patrick J. Stiff, Ran Reshef, Gowri Satyanarayana, Saurabh Dahiya, Hema Parmar, Wei Ye, Laurence Gamelin, Rajani Dinavahi	2021	8
2	ENTRATA: Randomized, double-blind, phase II study of telaglenastat (tela; CB-839) + everolimus (E) vs placebo (pbo) + E in patients (pts) with advanced/metastatic renal cell carcinoma (mRCC) Annals of Oncology ·Robert J. Motzer, Chung‐Han Lee, Hamid Emamekhoo, Marc Matrana, Ivor Percent, James J. Hsieh, Arif Hussain, Ulka N. Vaishampayan, R Graham, S. Liu, Steve McCune, Montaser Shaheen, Hema Parmar, Yuning Shen, Sam H. Whiting, Nizar M. Tannir	2019	22
3	Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors Cancer Discovery ·Dejan Juric, Ian E. Krop, Ramesh K. Ramanathan, Timothy R. Wilson, Joseph A. Ware, Sandra Sanabria Bohórquez, Heidi Savage, Deepak Sampath, Laurent Salphati, Ray Lin, Huan Jin, Hema Parmar, Jerry Y. Hsu, Daniel D. Von Hoff, José Baselga	2017	120
4	A multicenter, single‐arm, open‐label, phase 2 study of apitolisib (GDC‐0980) for the treatment of recurrent or persistent endometrial carcinoma (MAGGIE study) Cancer ·Vicky Makker, Fernando O. Recio, Ling Ma, Ursula A. Matulonis, Jennifer Lauchle, Hema Parmar, Houston Gilbert, Joseph A. Ware, Rui Zhu, Shan Lu, Ling‐Yuh Huw, Yulei Wang, Hartmut Koeppen, Jill M. Spoerke, Mark R. Lackner, Carol Aghajanian	2016	64
5	Abstract PD5-2: Ph1b study of the PI3K inhibitor taselisib (GDC-0032) in combination with letrozole in patients with hormone receptor-positive advanced breast cancer Cancer Research ·Cristina Saura, Jasgit C. Sachdev, Manish R. Patel, Andrés Cervantes, Dejan Juric, Jeffrey R. Infante, Donald Richards, Sandra Sanabria, Xuyang Lu, Joseph A. Ware, Timothy R. Wilson, Hema Parmar, Jerry Y. Hsu, Mafalda Oliveira, Eric P. Winer, Daniel D. Von Hoff, José Baselga, Ian E. Krop	2015	15
6	Abstract A03: Comprehensive predictive biomarker evaluation in two phase II clinical trials of the PI3K/mTOR inhibitor GDC-0980 in metastatic renal cell carcinoma and advanced endometrial cancer Molecular Cancer Therapeutics ·Jill M. Spoerke, Vicky Makker, Carol Aghajanian, Powles Thomas, Robert J. Motzer, Jennifer Lauchle, Hema Parmar, Houston Gilbert, Wei Lin, Bridget O’Keeffe, Michelle Byrtek, Hartmut Koeppen, Yulei Wang, Shan Lu, Ling‐Yuh Huw, Garret M. Hampton, Mark R. Lackner	2015	2
7	Abstract OT1-1-01: LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early stage breast cancer Cancer Research ·Cristina Saura, Evandro de Azambuja, Peter Dubsky, Mafalda Oliveira, Kamal S. Saini, Christian Fes, Ray Lin, Timothy R. Wilson, Jill Fredickson, Hema Parmar, Jerry Y. Hsu, Martine Piccard, Michael Gnant, José Baselga	2015	1
8	Phase II trial of GDC-0980 (dual PI3K/mTOR inhibitor) in patients with advanced endometrial carcinoma: Final study results. Journal of Clinical Oncology ·Vicky Makker, Fernando O. Recio, Ling Ma, Ursula A. Matulonis, Jennifer Lauchle, Hema Parmar, Houston Gilbert, Yulei Wang, Hartmut Koeppen, Jill M. Spoerke, Mark R. Lackner, Carol Aghajanian, (unknown)	2014	12
9	Abstract PD1-3: Ph1b study of the PI3K inhibitor GDC-0032 in combination with fulvestrant in patients with hormone receptor-positive advanced breast cancer Cancer Research ·Dejan Juric, Cristina Saura, Andrés Cervantes, Carla Kurkjian, MR Patel, Jasgit C. Sachdev, Ingrid Mayer, IE Krop, Mafalda Oliveira, Sandra Sanabria, Sravanthi Cheeti, RS Lin, R Graham, TR Wilson, Hema Parmar, JY Hsu, DD Von Hoff, José Baselga	2013	11
10	Abstract LB-64: GDC-0032, a beta isoform-sparing PI3K inhibitor: Results of a first-in-human phase Ia dose escalation study. Cancer Research ·Dejan Juric, Ian E. Krop, Ramesh K. Ramanathan, Jim Xiao, Sandra Sanabria, Timothy R. Wilson, YounJeong Choi, Hema Parmar, Jerry Y. Hsu, José Baselga, Daniel D. Von Hoff	2013	28
11	OCEANS: A randomized, double-blinded, placebo-controlled phase III trial of chemotherapy with or without bevacizumab (BEV) in patients with platinum-sensitive recurrent epithelial ovarian (EOC), primary peritoneal (PPC), or fallopian tube cancer (FTC). Journal of Clinical Oncology ·C. Aghajanian, N. Finkler, T. Rutherford, D. A. Smith, Jun-Mei Yi, Hema Parmar, Lawrence R. Nycum, Mika A. Sovak	2011	25
12	SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer Annals of Oncology ·EL Mayer, S. Dhakil, Taral Patel, S. Sundaram, C. J. Fabian, Mark Kozloff, R Qamar, Fabio Volterra, Hema Parmar, Meghna Samant, Harold J. Burstein	2010	37
13	SABRE-B: a randomized phase II trial evaluating the safety and efficacy of combining sunitinib (S) with paclitaxel (P) + bevacizumab (B) as first-line treatment for HER2-negative metastatic breast cancer (MBC): final results. Cancer Research ·Erica L. Mayer, Mark Kozloff, R Qamar, Barbara Klencke, Jai Balkissoon, Hema Parmar, Meghna Samant, HJ Burstein	2009	7
14	Identification of an epithelial-specific enhancer regulating ESX expression Gene ·Richard M. Neve, Hema Parmar, Cliff Amend, Chira Chen, Angie Rizzino, Christopher C. Benz	2005	10
15	Hyperplasia, reduced E-cadherin expression, and developmental arrest in mammary glands oxidatively stressed by loss of mitochondrial superoxide dismutase The Breast ·Hema Parmar, Simon Melov, Enrique Samper, Britt‐Marie Ljung, Gerald R. Cunha, Christopher C. Benz	2005	10
16	Estrogen Receptor β Inhibits Human Breast Cancer Cell Proliferation and Tumor Formation by Causing a G2 Cell Cycle Arrest Cancer Research ·Sreenivasan Paruthiyil, Hema Parmar, Vaishali Kerekatte, Gerald R. Cunha, Gary L. Firestone, Dale C. Leitman	2004	490
17	Epithelial–stromal interactions in the mouse and human mammary gland in vivo Endocrine Related Cancer ·Hema Parmar, Gerald R. Cunha	2004	141
18	A Novel Method for Growing Human Breast Epithelium in Vivo Using Mouse and Human Mammary Fibroblasts Endocrinology ·Hema Parmar, Peter Young, Joanne T. Emerman, Richard M. Neve, Shanaz H. Dairkee, Gerald R. Cunha	2002	62
19	Activity-regulated, cytoskeleton-associated protein (Arc) is essential for visceral endoderm organization during early embryogenesis Mechanisms of Development ·Dong Liu, Di Bei, Hema Parmar, Andrew Matus	2000	15
20	Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. PubMed ·Robert J. Motzer, Ashok Rakhit, Lawrence H. Schwartz, Thomas Olencki, Terri Malone, Kate Sandstrom, R Nadeau, Hema Parmar, Ronald M. Bukowski	1998	194

About Hema Parmar

Hema Parmar is a scholar working on Oncology, Genetics, Obstetrics and Gynecology, Pulmonary and Respiratory Medicine and Hematology, having authored 23 papers that have together received 1.4k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (5 papers), Advanced Breast Cancer Therapies (5 papers), PI3K/AKT/mTOR signaling in cancer (5 papers), Wnt/β-catenin signaling in development and cancer (3 papers), Chronic Lymphocytic Leukemia Research (3 papers), HER2/EGFR in Cancer Research (3 papers), Cancer Cells and Metastasis (3 papers) and Estrogen and related hormone effects (3 papers). The work is most often cited by research in Oncology (591 citations), Genetics (461 citations), Cancer Research (198 citations), Toxicology (34 citations) and Molecular Biology (656 citations). Hema Parmar has collaborated with scholars based in United States, Spain and Switzerland. Frequent co-authors include Gerald R. Cunha, Dale C. Leitman, Gary L. Firestone, Sreenivasan Paruthiyil, Andrew Matus, Robert J. Motzer, R Nadeau, Ashok Rakhit, Thomas Olencki and Ronald M. Bukowski. Their work appears in journals such as Cancer Research, Journal of Clinical Oncology, Annals of Oncology, Cancer and Gene.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact